Grant: Operating Grant
McGill University
$672,639.00
Exploiting A Novel Cation Binding Pocket on Kainate Receptors
EF 2013-14
Résumé
A major challenge for modern medicine is to develop better therapeutic approaches to treat the many disease states of the human brain. Although significant progress has been made in the last 20-30 years, a perennial problem has been to develop drugs that lack side-effects. This issue is often cited as one of the main reasons why so many patients stop taking prescribed medicine. Ionotropic glutamate receptors (iGluRs) are a family of signalling proteins in the brain that are implicated in many CNS disorders; from early childhood development (e.g. autism) to the aging brain (e.g. Alzheimer's disease, Parkinsonism). In this grant application, we plan to target a unique drug site on iGluRs that we believe will establish a new line of clinically-relevant compounds with few side-effects. The benefit of our work is that it may help treat the debilitating symptoms of patients suffering from epilepsy and/or neuropathic pain.
Programme
Operating Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
306595
Name
Bowie Derek
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Pharmacology & Toxicology
Projecttitle
Exploiting A Novel Cation Binding Pocket on Kainate Receptors
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$672,639
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Electrophysiology; Ion-Channel; Ionotropic Glutamate Receptor; Kainate Receptor; Neuroscience; Pharmacology
Abstract
A major challenge for modern medicine is to develop better therapeutic approaches to treat the many disease states of the human brain. Although significant progress has been made in the last 20-30 years, a perennial problem has been to develop drugs that lack side-effects. This issue is often cited as one of the main reasons why so many patients stop taking prescribed medicine. Ionotropic glutamate receptors (iGluRs) are a family of signalling proteins in the brain that are implicated in many CNS disorders; from early childhood development (e.g. autism) to the aging brain (e.g. Alzheimer's disease, Parkinsonism). In this grant application, we plan to target a unique drug site on iGluRs that we believe will establish a new line of clinically-relevant compounds with few side-effects. The benefit of our work is that it may help treat the debilitating symptoms of patients suffering from epilepsy and/or neuropathic pain.
Competitiondate
201403
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Bowie, Derek
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $672,639~ $0~
